Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.

Juang SH, Lung CC, Hsu PC, Hsu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang L, Chen TS, Chen SF, Fu KC, Hsu CL, Lin MJ, Chang CJ, Ashendel CL, Chan TC, Chou KM, Chang JY.

Mol Cancer Ther. 2007 Jan;6(1):193-202.

2.

Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones.

Bakare O, Ashendel CL, Peng H, Zalkow LH, Burgess EM.

Bioorg Med Chem. 2003 Jul 17;11(14):3165-70.

PMID:
12818679
3.

Characterization of the in vivo sites of serine phosphorylation on Lck identifying serine 59 as a site of mitotic phosphorylation.

Kesavan KP, Isaacson CC, Ashendel CL, Geahlen RL, Harrison ML.

J Biol Chem. 2002 Apr 26;277(17):14666-73. Epub 2002 Feb 14.

4.

Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes.

Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM.

J Biol Chem. 2001 Sep 14;276(37):34671-80. Epub 2001 Jul 18.

5.

Bioactive compounds from Psorothamnus junceus.

Zhang H, Li X, Ashendel CL, Chang CJ.

J Nat Prod. 2000 Sep;63(9):1244-8.

PMID:
11000028
6.

Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives.

Xu WC, Zhou Q, Ashendel CL, Chang CT, Chang CJ.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.

PMID:
10465561
7.

Novel protein kinase C inhibitors: alpha-terthiophene derivatives.

Kim DS, Ashendel CL, Zhou Q, Chang CT, Lee ES, Chang CJ.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2695-8.

PMID:
9873605
8.

Workgroup 3: transgenic and reconstitution models of prostate cancer.

Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI.

Prostate. 1998 Jun 15;36(1):59-63. No abstract available.

PMID:
9650918
9.

Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis.

Ramocki MB, Johnson SE, White MA, Ashendel CL, Konieczny SF, Taparowsky EJ.

Mol Cell Biol. 1997 Jul;17(7):3547-55.

10.

Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk.

Furlong MT, Mahrenholz AM, Kim KH, Ashendel CL, Harrison ML, Geahlen RL.

Biochim Biophys Acta. 1997 Feb 4;1355(2):177-90.

11.

Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.

Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Dorr R, Dvorakova K, Salmon S, Harrison S, Worzalla J.

Cancer Chemother Pharmacol. 1997;41(1):22-8.

PMID:
9443610
12.

Activation of T cell Raf-1 at mitosis requires the protein-tyrosine kinase Lck.

Pathan NI, Ashendel CL, Geahlen RL, Harrison ML.

J Biol Chem. 1996 Nov 29;271(48):30315-7.

13.

ras downregulation of protein kinase C mRNA in C3H 10T1/2 fibroblasts.

Fernandes ER, Ashendel CL.

Mol Carcinog. 1996 Sep;17(1):23-34.

PMID:
8876672
14.

Oncogene signal transduction inhibitors from medicinal plants.

Chang CJ, Ashendel CL, Geahlen RL, McLaughlin JL, Waters DJ.

In Vivo. 1996 Mar-Apr;10(2):185-90.

PMID:
8744799
15.

Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.

Frew T, Powis G, Berggren M, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Hudson C, Gruszecka-Kowalik E, Burgess EM, et al.

Anticancer Drug Des. 1995 Jun;10(4):347-59.

PMID:
7786399
16.

Diet, signal transduction and carcinogenesis.

Ashendel CL.

J Nutr. 1995 Mar;125(3 Suppl):686S-691S. doi: 10.1093/jn/125.suppl_3.686S. Review.

PMID:
7884552
17.

Advances with phospholipid signalling as a target for anticancer drug development.

Powis G, Berggren M, Gallegos A, Frew T, Hill S, Kozikowski A, Bonjouklian R, Zalkow L, Abraham R, Ashendel C, et al.

Acta Biochim Pol. 1995;42(4):395-403. Review.

18.

Isolation and characterization of the principal ATPase associated with transitional endoplasmic reticulum of rat liver.

Zhang L, Ashendel CL, Becker GW, Morré DJ.

J Cell Biol. 1994 Dec;127(6 Pt 2):1871-83.

19.

A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors.

Frew T, Powis G, Berggren M, Abraham RT, Ashendel CL, Zalkow LH, Hudson C, Qazia S, Gruszecka-Kowalik E, Merriman R, et al.

Anticancer Res. 1994 Nov-Dec;14(6B):2425-8.

PMID:
7872663
20.

A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity.

Hill SR, Bonjouklian R, Powis G, Abraham RT, Ashendel CL, Zalkow LH.

Anticancer Drug Des. 1994 Aug;9(4):353-61.

PMID:
7916901
21.

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, et al.

Cancer Res. 1994 May 1;54(9):2419-23.

22.

Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.

Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Grindey GB, Bonjouklian R.

Cancer Chemother Pharmacol. 1994;34(4):344-50.

PMID:
8033301
23.

Kinase inhibitors from Polygonum cuspidatum.

Jayatilake GS, Jayasuriya H, Lee ES, Koonchanok NM, Geahlen RL, Ashendel CL, McLaughlin JL, Chang CJ.

J Nat Prod. 1993 Oct;56(10):1805-10.

PMID:
8277318
24.

Treatment of T cells with 2-hydroxymyristic acid inhibits the myristoylation and alters the stability of p56lck.

Nadler MJ, Harrison ML, Ashendel CL, Cassady JM, Geahlen RL.

Biochemistry. 1993 Sep 7;32(35):9250-5.

PMID:
8103677
25.

Hemicholinium and related lipids: inhibitors of protein kinase C.

Kumaravel G, Ashendel CL, Gandour RD.

J Med Chem. 1993 Jan 8;36(1):177-8. No abstract available.

PMID:
8421285
26.

Partial suppression of tumorigenicity in a human lung cancer cell line transfected with Krev-1.

Caamano J, DiRado M, Iizasa T, Momiki S, Fernandes E, Ashendel C, Noda M, Klein-Szanto AJ.

Mol Carcinog. 1992;6(4):252-9.

PMID:
1485916
28.

Inhibition of myogenesis by the H-ras oncogene: implication of a role for protein kinase C.

Vaidya TB, Weyman CM, Teegarden D, Ashendel CL, Taparowsky EJ.

J Cell Biol. 1991 Aug;114(4):809-20.

29.

Isolation of cloned mouse protein kinase C beta-II cDNA and its sequence.

Tang YM, Ashendel CL.

Nucleic Acids Res. 1990 Sep 11;18(17):5310. No abstract available.

30.

Partial characterization of epidermal protein kinase C in mice sensitive or resistant to phorbol ester.

Hirabayashi N, Warren BS, Wang XJ, Petersen-Marht S, Beltran L, Davis MM, Ashendel CL, DiGiovanni J.

Mol Carcinog. 1990;3(3):171-80.

PMID:
2372371
31.
32.

Partial down-regulation of protein kinase C in C3H 10T 1/2 mouse fibroblasts transfected with the human Ha-ras oncogene.

Weyman CM, Taparowsky EJ, Wolfson M, Ashendel CL.

Cancer Res. 1988 Nov 15;48(22):6535-41.

33.

Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells.

Kraft AS, Reeves JA, Ashendel CL.

J Biol Chem. 1988 Jun 15;263(17):8437-42.

34.
35.

The phorbol ester receptor: a phospholipid-regulated protein kinase.

Ashendel CL.

Biochim Biophys Acta. 1985 Sep 9;822(2):219-42. Review. No abstract available.

PMID:
3161542
36.

Protein kinase activity associated with a phorbol ester receptor purified from mouse brain.

Ashendel CL, Staller JM, Boutwell RK.

Cancer Res. 1983 Sep;43(9):4333-7.

37.
38.
39.

Identification of a calcium- and phospholipid- dependent phorbol ester binding activity in the soluble fraction of mouse tissues.

Ashendel CL, Staller JM, Boutwell RK.

Biochem Biophys Res Commun. 1983 Feb 28;111(1):340-5.

PMID:
6830598
40.

Observations on the mechanism of skin tumor promotion by phorbol esters.

Boutwell RK, Takigawa M, Verma AK, Ashendel CL.

Princess Takamatsu Symp. 1983;14:177-93. Review.

PMID:
6240487
42.

Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis.

Boutwell RK, Verma AK, Ashendel CL, Astrup E.

Carcinog Compr Surv. 1982;7:1-12. Review.

PMID:
6802487
43.

Direct measurement of specific binding of highly lipophilic phorbol diester to mouse epidermal membranes using cold acetone.

Ashendel CL, Boutwell RK.

Biochem Biophys Res Commun. 1981 Mar 31;99(2):543-9. No abstract available.

PMID:
7236282
47.

Prostaglandin E and F levels in mouse epidermis are increased by tumor-promoting phorbol esters.

Ashendel CL, Boutwell RK.

Biochem Biophys Res Commun. 1979 Sep 27;90(2):623-7. No abstract available.

PMID:
508324
48.

The induction of ornithine decarboxylase activity and its control in mouse skin epidermis.

Boutwell RK, O'Brien TG, Verma AK, Weekes RG, DeYoung LM, Ashendel CL, Astrup EG.

Adv Enzyme Regul. 1978;17:89-112. No abstract available.

PMID:
757315

Supplemental Content

Loading ...
Support Center